Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US

被引：0
|
作者：
Buthainah Ghanem
Lu Shi
机构：
[1] Chapman University,Department of Pharmaceutical Economics and Policy, School of Pharmacy
[2] Oregon State University,College of Public Health and Human Sciences
来源：
Clinical Drug Investigation | 2022年 / 42卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1085 / 1092
页数：7
相关论文
共 50 条
  • [1] Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US
    Ghanem, Buthainah
    Shi, Lu
    CLINICAL DRUG INVESTIGATION, 2022, 42 (12) : 1085 - 1092
  • [2] Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
    Munshi, Nikhil C.
    Anderson, Larry D., Jr.
    Shah, Nina
    Madduri, Deepu
    Berdeja, Jesus
    Lonial, Sagar
    Raje, Noopur
    Lin, Yi
    Siegel, David
    Oriol, Albert
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Cavo, Michele
    Einsele, Hermann
    Goldschmidt, Hartmut
    Weisel, Katja
    Rambaldi, Alessandro
    Reece, Donna
    Petrocca, Fabio
    Massaro, Monica
    Connarn, Jamie N.
    Kaiser, Shari
    Patel, Payal
    Huang, Liping
    Campbell, Timothy B.
    Hege, Kristen
    San-Miguel, Jesus
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (08): : 705 - 716
  • [3] Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma
    Little, Jessica S.
    Shah, Parth
    Sperling, Adam S.
    Branagan, Andrew R.
    Nadeem, Omar
    Yee, Andrew J.
    Raje, Noopur S.
    Munshi, Nikhil C.
    Hammond, Sarah
    BLOOD, 2021, 138 : 3839 - +
  • [4] The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US
    Buthainah Ghanem
    Lu Shi
    BioDrugs, 2022, 36 : 773 - 780
  • [5] The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US
    Ghanem, Buthainah
    Shi, Lu
    BIODRUGS, 2022, 36 (06) : 773 - 780
  • [6] FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma
    Sharma, Poornima
    Kanapuru, Bindu
    George, Bindu
    Lin, Xue
    Xu, Zhenzhen
    Bryan, Wilson W.
    Pazdur, Richard
    Theoret, Marc R.
    CLINICAL CANCER RESEARCH, 2022, 28 (09) : 1759 - 1764
  • [7] Idecabtagene vicleucel for relapsed/refractory multiple myeloma: a review of recent advances
    Tu, Wei
    Xiao, Yajuan
    Wang, Yadong
    Luo, Rongcheng
    Chen, Zhe-Sheng
    DRUGS OF TODAY, 2022, 58 (03) : 117 - 132
  • [8] Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
    Parrondo, Ricardo D.
    Sam, Keren
    Rasheed, Ahsan
    Alegria, Victoria
    Sher, Taimur
    Roy, Vivek
    Chanan-Khan, Asher
    Ailawadhi, Sikander
    BLOOD CANCER JOURNAL, 2022, 12 (04)
  • [9] Characterizing the exposure-response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma
    Connarn, Jamie N.
    Witjes, Han
    van Zutphen-van Geffen, Marielle
    de Greef, Rik
    Campbell, Timothy B.
    Hege, Kristen
    Zhou, Simon
    Lamba, Manisha
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (11): : 1687 - 1697
  • [10] Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial
    McGarvey, November
    Ung, Brian
    Carattini, Thomas
    Imanak, Ken
    Lee, Abraham
    Campbell, Timothy B.
    Patwardhan, Pallavi
    ADVANCES IN THERAPY, 2023, 40 (10) : 4626 - 4638
12345